30 closest matches · ranked by relevance
Peripheral T-cell Lymphoma
Primary: Percentage of Participants With a Complete Response According to the International Workshop Response Criteria (IWC) for Non-Hodgkin's Lymphomas (NHL) Assessed by an…
Peripheral T-Cell Lymphoma
Primary: Tumor Response (Central Assessment) — 19.3; 45.6 percentage of participants
T-Cell Lymphoma Relapsed · T-Cell Lymphoma Refractory
Primary: Best Overall Response Rate During the First 8 Cycles of Treatment — 5 Participants
Peripheral T-cell Lymphoma
Primary: Objective Response Rate — 25.8 percentage of participants
Relapsed Peripheral T-Cell Lymphoma · Refractory Peripheral T-Cell Lymphoma
Primary: Overall Response Rate (ORR) Based on Independent Review Committee (IRC) Assessment — 33; 45 percentage of participants — p=0.038
Adult Nasal Type Extranodal NK/T-Cell Lymphoma · Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-Cell Lymphoma
Primary: Objective Response Rate (Complete Responses (CR) + Partial Responses (PR)) — 2; 7; 28 participants
Peripheral T-Cell Lymphoma (PTCL)
Primary: Objective Response Rate — 21 Participants
Peripheral T Cell Lymphoma
Primary: Overall Response Rate (ORR) at Four Months (LYRIC Criteria) — 2; 0; 1 Participants
Anaplastic Large Cell Lymphoma, ALK-Negative · Anaplastic Large Cell Lymphoma, ALK-Positive · Hepatosplenic T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP — 10 milligrams
Peripheral T-cell Lymphoma
Primary: Complete Remission (CR) Rate — 3 Participants
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT Imaging — 260; 260; 232 days
Peripheral T-cell Lymphoma
Primary: Progression-free Survival — 35; 27 participants
Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Overall Response Rate — 1; 1; 3; 1 Participants
Relapsed or Refractory Peripheral T-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 56.3; 7.1; 40.0; 0.0 percentage of participants — p=0.000
Refractory Peripheral T-Cell Lymphoma · Relapsed T-Cell Lymphoma
Primary: Objective Response Rate(ORR) by International Working Group Criteria — 37 Participants
Peripheral T Cell Lymphoma
Primary: Efficacy: Complete Response Rate — 11 Participants — p=.1
Lymphoma, T-Cell
Primary: Objective Response Rate — 8 percentage of patients
Lymphoma, T-Cell, Peripheral
Primary: Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants — 63.3; 46.9; 40.8; 40.8 Percentage of participants
Peripheral T-cell Lymphoma
Primary: Response Rate Per Independent Central Review — 32 of Patients who Responded
Peripheral T-cell Lymphoma · Cutaneous T-cell Lymphoma
Primary: Objective Response Rate (ORR) — 41.2; 31.6 percentage of participants
Cutaneous T-Cell Lymphoma · Mature T-cell Malignancies · Peripheral T-Cell Lymphoma
Primary: Maximum Tolerated Dose (MTD) — 20 mg/day
Lymphoma
Primary: 3 Year Progression-Free Survival Rate — 30 percentage of participants
T Cell Lymphoma
Primary: Overall Response Rate — 5 participants
Lymphoma, Non-Hodgkin's
Primary: Overall Response Rate — 53.8 percentage of participants
Peripheral T-cell Lymphoma
Primary: Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano Criteria — 53.8; 53.8 percentage of participants
B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia · B-cell Chronic Lymphocytic Leukemia
Primary: Disease Relapse Rate — 18 Participants
Lymphoma, T-cell, Peripheral
Primary: Number of Participants With Dose-limiting Toxicity (DLT) in Accordance With National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE)…
Relapsed or Refractory Lymphoproliferative Malignancies · Hodgkin's Lymphoma · Peripheral T-cell Lymphoma
Primary: Objective Responses Assessed by International Workshop Criteria (IWC) — 8; 5; 7 participants
T Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate — 0.0 proportion of participants
Prolymphocytic Leukemia · Recurrent Adult Hodgkin Lymphoma · Recurrent Childhood Hodgkin Lymphoma
Primary: Engraftment of HLA Identical PBSC Allografts — 53 Participants